Top

Published in:

Open Access 01-12-2008 | Review

Adaptive design methods in clinical trials – a review

Authors: Shein-Chung Chow, Mark Chang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2008

Abstract

In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular due to its flexibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent (ad hoc), and retrospective adaptive designs. An adaptive design allows modifications made to trial and/or statistical procedures of ongoing clinical trials. However, it is a concern that the actual patient population after the adaptations could deviate from the originally target patient population and consequently the overall type I error (to erroneously claim efficacy for an infective drug) rate may not be controlled. In addition, major adaptations of trial and/or statistical procedures of on-going trials may result in a totally different trial that is unable to address the scientific/medical questions the trial intends to answer. In this article, several commonly considered adaptive designs in clinical trials are reviewed. Impacts of ad hoc adaptations (protocol amendments), challenges in by design (prospective) adaptations, and obstacles of retrospective adaptations are described. Strategies for the use of adaptive design in clinical development of rare diseases are discussed. Some examples concerning the development of Velcade intended for multiple myeloma and non-Hodgkin's lymphoma are given. Practical issues that are commonly encountered when implementing adaptive design methods in clinical trials are also discussed.

Available only for authorised users

Woodcock J: "FDA introduction comments: clinical studies design and evaluation issues". Clinical Trials. 2005, 2: 273-275. 10.1191/1740774505cn096oa.CrossRefPubMed

Wei LJ: "The adaptive biased-coin design for sequential experiments". Annal of Statistics. 1978, 9: 92-100. 10.1214/aos/1176344068.CrossRef

Efron B: "Forcing a sequential experiment to be balanced". Biometrika. 1971, 58: 403-417. 10.1093/biomet/58.3.403.CrossRef

Lachin JM: "Statistical properties of randomization in clinical trials". Controlled Clinical Trials. 1988, 9: 289-311. 10.1016/0197-2456(88)90045-1.CrossRefPubMed

Rosenberger WF, Stallard N, Ivanova A, Harper CN, Ricks ML: "Optimal adaptive designs for binary response trials". Biometrics. 2001, 57: 909-913. 10.1111/j.0006-341X.2001.00909.x.CrossRefPubMed

Hardwick JP, Stout QF: "Optimal few-stage designs". Journal of Statistical Planning and Inference. 2002, 104: 121-145. 10.1016/S0378-3758(01)00242-7.CrossRef

Lan KKG, DeMets DL: "Group sequential procedures: calendar versus information time". Statistics in Medicine. 1987, 8: 1191-1198. 10.1002/sim.4780081003.CrossRef

Wang SK, Tsiatis AA: "Approximately optimal one-parameter boundaries for a sequential trials". Biometrics. 1987, 43 (1): 193-200. 10.2307/2531959.CrossRefPubMed

Posch M, Bauer P: "Adaptive two-satge designs and the conditional error function". Biometrical Journal. 1999, 41: 689-696. 10.1002/(SICI)1521-4036(199910)41:6<689::AID-BIMJ689>3.0.CO;2-P.CrossRef

10.

Lehmacher W, Wassmer G: "Adaptive sample size calculations in group sequential trials". Biometrics. 1999, 55: 1286-1290. 10.1111/j.0006-341X.1999.01286.x.CrossRefPubMed

11.

Liu Q, Proschan MA, Pledger GW: "A unified theory of two-stage adaptive designs". Journal of American Statistical Association. 2002, 97: 1034-1041. 10.1198/016214502388618852.CrossRef

12.

Jennison C, Turnbull BW: Group Sequential Methods with Applications to Clinical Trials. 2000, Chapman and Hall, New York, NY

13.

Jennison C, Turnbull BW: "Meta-analysis and adaptive group sequential design in the clinical development process". J Biopharm Stat. 2005, 15 (4): 537-558. 10.1081/BIP-200062273.CrossRefPubMed

14.

Cui L, Hung HMJ, Wang SJ: "Modification of sample size in group sequential trials". Biometrics. 1999, 55: 853-857. 10.1111/j.0006-341X.1999.00345.x.CrossRefPubMed

15.

Shih WJ: "Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison". Statistics in Medicine. 2006, 25: 933-941. 10.1002/sim.2252.CrossRefPubMed

16.

Chung-Stein C, Anderson K, Gallo P, Collins S: "Sample size reestimation: a review and recommendations". Drug Information Journal. 2006, 40: 475-484.

17.

EMEA: (2002, 2006). Point to Consider on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. CPMP/EWP/2459/02, London, UK.

18.

Chow SC, Chang M: Adaptive Design Methods in Clinical Trials. 2006, Chapman and Hall/CRC Press, Taylor and Francis, New York, NYCrossRef

19.

Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J: "Adaptive design in clinical drug development – an executive summary of the PhRMA Working Group (with discussions)". Journal of Biopharmaceutical Statistics. 2006, 16 (3): 275-283. 10.1080/10543400600614742.CrossRefPubMed

20.

Chang M: Adaptive Design Theory and Implementation Using SAS and R. 2007, Chapman and Hall/CRC Press, Taylor and Francis, New York, NY

21.

Chow SC, Chang M, Pong A: "Statistical consideration of adaptive methods in clinical development". Journal of Biopharmaceutical Statistics. 2005, 15: 575-591. 10.1081/BIP-200062277.CrossRefPubMed

22.

Proschan MA, Hunsberger SA: "Designed extension of studies based on conditional power". Biometrics. 1995, 51: 1315-1324. 10.2307/2533262.CrossRefPubMed

23.

Liu Q, Chi GYH: "On sample size and inference for two-stage adaptive designs". Biometrics. 2001, 57: 172-177. 10.1111/j.0006-341X.2001.00172.x.CrossRefPubMed

24.

Friede T, Kieser M: "Sample size recalculation for binary data in internal pilot study designs". Pharmaceutical Statistics. 2004, 3: 269-279. 10.1002/pst.140.CrossRef

25.

Proschan MA: "Two-stage sample size re-estimation based on a nuisance parameter: a review". Journal of Biopharmaceutical Statistics. 2005, 15: 539-574.

26.

Hung HMJ, Cui L, Wang SJ, Lawrence J: "Adaptive statistical analysis following sample size modification based on interim review of effect size". Journal of Biopharmaceutical Statistics. 2005, 15: 693-706. 10.1081/BIP-200062855.CrossRefPubMed

27.

Bauer P, Kieser M: "Combining different phases in development of medical treatments within a single trial". Statistics in Medicine. 1999, 18: 1833-1848. 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.0.CO;2-3.CrossRefPubMed

28.

Brannath W, Koening F, Bauer P: "Improved repeated confidence bounds in trials with a maximal goal". Biometrical Journal. 2003, 45: 311-324. 10.1002/bimj.200390014.CrossRef

29.

Sampson AR, Sill MW: "Drop-the-loser design: normal case (with discussions)". Biometrical Journal. 2005, 47: 257-281. 10.1002/bimj.200410119.CrossRefPubMed

30.

Posch M, Koenig F, Branson M, Brannatch W, Dunger-Baldauf C, Bauer P: "Testing and estimation in flexible group sequential designs with adaptive treatment selection". Statistics in Medicine. 2005, 24: 3697-3714. 10.1002/sim.2389.CrossRefPubMed

31.

Bauer P, Rohmel J: "An adaptive method for establishing a dose-response relationship". Statistics in Medicine. 1995, 14: 1595-1607. 10.1002/sim.4780141410.CrossRefPubMed

32.

Whitehead J: Bayesian decision procedures with application to dose-finding studies. International Journal of Pharmaceutical Medicine. 1997, 11: 201-208.

33.

Zhang W, Sargent DJ, Mandrekar S: "An adaptive dose-finding design incorporating both toxicity and efficacy". Statistics in Medicine. 2006, 25: 2365-2383. 10.1002/sim.2325.CrossRefPubMed

34.

O'Quigley J, Pepe M, Fisher L: "Continual reassessment method: A practical design for phase I clinical trial in cancer". Biometrics. 1990, 46: 33-48. 10.2307/2531628.CrossRefPubMed

35.

O'Quigley J, Shen L: "Continual reassessment method: A likelihood approach". Biometrics. 1996, 52: 673-684. 10.2307/2532905.CrossRefPubMed

36.

Chang M, Chow SC: "A hybrid Bayesian adaptive design for dose response trials". Journal of Biopharmaceutical Statistics. 2005, 15: 667-691. 10.1081/BIP-200062288.CrossRef

37.

Mugno R, Zhus W, Rosenberger WF: "Adaptive urn designs for estimating several percentiles of a dose response curve". Statistics in Medicine. 2004, 23: 2137-2150. 10.1002/sim.1808.CrossRefPubMed

38.

Charkravarty A: Regulatory aspects in using surrogate markers in clinical trials. The Evaluation of Surrogate Endpoint. Edited by: Burzykowski, Molenberghs, Buyse. 2005, Springer, New York, NY

39.

Wang SJ, O'Neill RT, Hung HMJ: Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics. 2007, 6 (3): 227-244. 10.1002/pst.300.CrossRefPubMed

40.

Branson M, Whitehead W: "Estimating a treatment effect in survival studies in which patients switch treatment". Statistics in Medicine. 2002, 21: 2449-2463. 10.1002/sim.1219.CrossRefPubMed

41.

Hommel G: "Adaptive modifications of hypotheses after an interim analysis". Biometrical Journal. 2001, 43: 581-589. 10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>3.0.CO;2-J.CrossRef

42.

Kelly PJ, Stallard N, Todd S: "An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several". Journal of Biopharmaceutical Statistics. 2005, 15: 641-658. 10.1081/BIP-200062857.CrossRefPubMed

43.

Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M: "Adaptive seamless phase II/III designs – background, operational aspects, and examples". Drug Information Journal. 2006, 40: 463-474.

44.

Tsiatis AA, Mehta C: "On the inefficiency of the adaptive design for monitoring clinical trials". Biometrika. 2003, 90: 367-378. 10.1093/biomet/90.2.367.CrossRef

45.

Chow SC, Lu Q, Tse SK: "Statistical analysis for two-stage adaptive design with different study points". Journal of Biopharmaceutical Statistics. 2007, 17: 1163-1176. 10.1080/10543400701645249.CrossRefPubMed

46.

Quinlan JA, Krams M: "Implementing adaptive designs: logistical and operational consideration". Drug Information Journal. 2006, 40: 437-444.

47.

Chow SC, Shao J: "Inference for clinical trials with some protocol amendments". Journal of Biopharmaceutical Statistics. 2005, 15: 659-666. 10.1081/BIP-200062286.CrossRefPubMed

48.

Feng H, Shao J, Chow SC: "Group sequential test for clinical trials with moving patient population". Journal of Biopharmaceutical Statistics. 2007, 17: 1227-1238. 10.1080/10543400701645512.CrossRefPubMed

49.

Chang M: "Adaptive design method based on sum of p-values". Statistics in Medicine. 2007, 26: 2772-2784. 10.1002/sim.2755.CrossRefPubMed

50.

Wang SJ, Hung HMJ, O'Neill RT: Adapting the sample-size planning of a phase III trial based on phase II data. Pharmaceut. Statist. 2006

51.

Ellenberg SS, Fleming TR, DeMets DL: Data Monitoring Committees in Clinical Trials A Practical Perspective. 2002, John Wiley and Sons, New YorkCrossRef

52.

Pocock SJ: When (not) to stop a clinical trial for benefit. Journal of American Medical Association. 2005, 294: 2228-2230. 10.1001/jama.294.17.2228.CrossRef

53.

Wang SJ: Regulatory experience of adaptive designs in well-controlled clinical trials. Presented at Adaptive Designs: Opportunities, Challenges and Scope in Drug Development, Washington, DC. 2006

Title: Adaptive design methods in clinical trials – a review
Authors: Shein-Chung Chow
Mark Chang
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2008
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/1750-1172-3-11

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adaptive design methods in clinical trials – a review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

The inv dup (15) or idic (15) syndrome (Tetrasomy 15q)

Cluster headache

Multiple osteochondromas

Idiopathic pulmonary fibrosis

Brachydactyly

Asbestos-related pleural and lung fibrosis in patients with retroperitoneal fibrosis